

GLAXOSMITHKLINE PLC - RESULT OF AGM

GlaxoSmithKline plc (GSK) announces that at its Annual General Meeting (AGM) today, all resolutions were passed by shareholders.

GlaxoSmithKline AGM Poll Results

The following table shows the votes cast for each resolution:

Resolution	Total votes for*	%	Total votes against	%	Total votes cast	Votes withheld**
1 Adoption of Directors' Report and Financial Statements	3,827,705,365	98.70	50,361,254	1.30	3,878,066,619	3,315,549
2 Approval of the Remuneration Report	3,641,744,377	95.70	163,812,052	4.30	3,805,556,429	75,828,261
3 Re-election of Sir Christopher Gent	3,757,599,321	96.90	120,406,731	3.10	3,878,006,052	3,377,349
4 Re-election of Sir Andrew Witty	3,874,304,280	99.90	3,878,779	0.10	3,878,183,059	3,214,858
5 Re-election of Professor Sir Roy Anderson	3,874,110,361	99.90	3,788,474	0.10	3,877,898,835	3,482,154
6 Re-election of Dr Stephanie Burns	3,874,188,220	99.90	3,706,042	0.10	3,877,894,262	3,485,110
7 Re-election of Stacey Cartwright	3,871,534,437	99.84	6,292,248	0.16	3,877,826,685	3,552,308
8 Re-election of Larry Culp	3,863,938,369	99.65	13,752,888	0.35	3,877,691,257	3,689,401
9 Re-election of Sir Crispin Davis	3,872,742,523	99.87	5,082,798	0.13	3,877,825,321	3,554,050
10 Re-election of Simon Dingemans	3,873,781,085	99.90	3,931,792	0.10	3,877,712,877	3,666,495
11 Re-election of Judy Lewent	3,871,977,307	99.85	5,954,264	0.15	3,877,931,571	3,447,684
12 Re-election of Sir Deryck Maughan	3,865,657,282	99.69	12,144,052	0.31	3,877,801,334	3,578,315
13 Re-election of Dr Daniel Podolsky	3,867,010,327	99.72	10,760,012	0.28	3,877,770,339	3,608,654
14 Re-election of Dr Moncef Slaoui	3,873,750,729	99.89	4,223,699	0.11	3,877,974,428	3,406,260
15 Re-election of Tom de Swaan	3,798,800,827	97.96	78,991,586	2.04	3,877,792,413	3,586,579

Resolution		Total votes for*	%	Total votes against	%	Total votes cast	Votes withheld**
16	Re-election of Sir Robert Wilson	3,873,643,265	99.89	4,247,312	0.11	3,877,890,577	3,489,128
17	Re-appointment of auditors	3,796,598,526	99.27	27,986,430	0.73	3,824,584,956	56,794,117
18	Remuneration of auditors	3,843,027,589	99.46	20,772,856	0.54	3,863,800,445	17,579,487
19	Authority for the company to make donations to political organisations and incur political expenditure	3,806,217,378	98.23	68,562,707	1.77	3,874,780,085	6,605,082
20	Authority to allot shares	3,773,307,135	97.35	102,769,873	2.65	3,876,077,008	5,304,590
21	Disapplication of pre-emption rights***	3,833,012,357	98.94	40,945,524	1.06	3,873,957,881	7,422,017
22	Authority for the company to purchase its own shares***	3,860,354,462	99.55	17,589,398	0.45	3,877,943,860	3,443,301
23	Exemption from statement of senior statutory auditor's name	3,852,410,960	99.51	18,979,169	0.49	3,871,390,129	9,991,468
24	Authorise reduced notice of a general meeting other than an AGM***	3,521,062,642	90.83	355,321,668	9.17	3,876,384,310	4,998,426
25	Renew the GSK ShareSave Plan	3,791,116,168	97.83	83,969,018	2.17	3,875,085,186	6,344,467
26	Renew the GSK ShareReward Plan	3,832,667,502	98.91	42,189,238	1.09	3,874,856,740	6,574,197

Notes:

* Includes discretionary votes.

** A vote withheld is not a vote in law and is not counted in the calculation of the proportion of votes "For" or "Against" a resolution.

*** Indicates Special Resolutions requiring a 75% majority.

James Murdoch did not stand for re-election as a Director, and has stepped down from the Board with effect from noon today.

The following table provides further relevant information:

	GlaxoSmithKline's Twelfth AGM (2012)	GlaxoSmithKline's Eleventh AGM (2011)
Issued share capital (excluding Treasury Shares)	5,046,404,827	5,163,907,153
Total votes cast and votes withheld lodged as a % of GSK's issued share capital (excluding Treasury Shares)	76.91%	74.72%
Total shareholder population	147,408	155,990
Total number of proxies lodged	9,717	9,886
% of shareholders who lodged proxies	6.59%	6.34%
Number of shareholders, corporate representatives and proxies who attended the AGM	426	364

V A Whyte
Company Secretary
3 May 2012

These results will shortly be available on the company's website at www.gsk.com.

GlaxoSmithKline Enquiries:

UK Media enquiries:	David Mawdsley	+44 (0) 20 8047 5502	(London)
	Stephen Rea	+44 (0) 20 8047 5502	(London)
	Sarah Spencer	+44 (0) 20 8047 5502	(London)
	David Daley	+44 (0) 20 8047 5502	(London)
US Media enquiries:	Kevin Colgan	+1 919 483 2839	(North Carolina)
	Melinda Stubbee	+1 919 483 2839	(North Carolina)
	Sarah Alspach	+1 919 483 2839	(Washington, DC)
	Jennifer Armstrong	+1 919 483 2839	(Philadelphia)
Analyst/Investor enquiries:	Sally Ferguson	+44 (0) 20 8047 5543	(London)
	Tom Curry	+ 1 215 751 5419	(Philadelphia)
	Gary Davies	+ 44 (0) 20 8047 5503	(London)
	Jeff McLaughlin	+ 1 215 751 7002	(Philadelphia)
	Ziba Shamsi	+ 44 (0) 20 8047 3289	(London)